For Pamorelin LA and Salvacyl in Switzerland, Debiopharm Group has entered into a distribution and commercialization deal with Vifor Pharma.
Pamorelin LA is indicated to treat advanced hormone-dependent prostate cancer, endometriosis and female infertility and Salvacyl is indicated to treat severe sexual deviation in men.
Vifor Pharma Swiss affiliate general manager Josef Troxler stated that, \"With Debiopharm we have found a renowned Swiss partner. This move will enable us to provide patients and doctors with an innovative product in the areas of oncology and gynaecology.\"
According to Vifor Pharma the one and three-month formulations of Pamorelin LA are available on immediate basis and at a later date, the company is to announced the availability of six-month formulation of Pamorelin LA and Salvacyl.
Pamorelin LA is indicated to treat advanced hormone-dependent prostate cancer, endometriosis and female infertility and Salvacyl is indicated to treat severe sexual deviation in men.
Vifor Pharma Swiss affiliate general manager Josef Troxler stated that, \"With Debiopharm we have found a renowned Swiss partner. This move will enable us to provide patients and doctors with an innovative product in the areas of oncology and gynaecology.\"
According to Vifor Pharma the one and three-month formulations of Pamorelin LA are available on immediate basis and at a later date, the company is to announced the availability of six-month formulation of Pamorelin LA and Salvacyl.